PFO Global And GB Pharma Holdings Collaborate On High Quality Prescription Lenses For Africa

IRVING, TX--(Marketwired - December 03, 2015) - PFO Global, Inc. (OTCQB: PFGB), the innovative manufacturer and commercial provider of advanced prescription lenses, finished eyewear and vision technologies, today announced an agreement with GB Pharma Holdings LLC. to bring cost effective and high quality prescription lenses and finished eyewear to Africa and various distribution channels in the USA.

“We are excited to work with PFO Global to bring quality prescription eyewear to Africa and underserved communities in the USA,” stated Dr. Gloria Herndon, CEO of GB Pharma Holdings Inc. “We work with international agencies and regulatory bodies to bring cost effective, quality medical products to Africa. PFO Global’s prescription lenses are an incredible addition to our product line.”

Rudolf Suter, President and CEO of PFO Global, Inc., said, “We’re honored to join forces with GB Pharma Holdings and Dr. Herndon in an effort to advance vision solutions available to Africa. According to the World Health Organization, the region has nearly 153 million people with visual impairment due to uncorrected refractive errors. Approximately 80% of the causes of visual impairment including blindness are believed to be avoidable.”

Suter continued, “We believe our partnership with GB Pharma presents PFO Global with the unique opportunity to not only expand our business and address a sizeable untapped market, but to also play a positive role in the fight against blindness by providing eye care services to a region currently grossly underserved.”

About PFO Global
PFO Global is an innovative manufacturer and commercial provider of advanced prescription lenses, finished eyewear and vision technologies targeted for the global optometrists marketplace. PFO Global’s uniquely interactive manufacturing, fulfillment and proprietary online ordering systems combine with its eyewear lens product lines intended to meet the broad array of eyewear markets, from the independent eye care professional offices to finished eyewear products for US Healthcare Entitlement Programs, such as Medicaid and Medicare. Products include: EYEX3, Complete Eyewear, SmartCalc™, Identity™/Acuity™ and Upgrade™ (Digital Free-Form Lenses), Resolution™ Polycarbonate Lens, Hyper Index™ by ASAHI LITE and VITARIS™. For more information, please visit www.pfoglobal.com.

About GB Pharma Holdings LLC.
GB Pharma Holdings is a Washington D.C. based global Pharmaceutical company with expertise in defining policies, facilitating approvals, distribution and cGMP (Good Manufacturing Practices). Additionally it is a comprehensive pharmaceutical management and consulting service agency, wholesale pharmaceutical distributor, and conduit for accessing quality international pharmaceutical, medical and Healthcare products.. For more information, please visit www.gbgroupglobal.com / www.gbpharmaholdings.com.

Safe Harbor Statement
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the Securities and Exchange Commission (the “SEC”), not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.